|
End-of-day quote
Korea S.E.
2026-08-21
|
5-day change | 1st Jan Change | ||
| 5,390.00 KRW | -7.39% |
|
-5.27% | -20.97% |
| Dec. 09 | GC Genome Study Identifies 'Confounders' Interfering with Cancer Signals to Improve Liquid Biopsy Accuracy | CI |
| 25-06-12 | GC Genome Shares Decline Nearly 3% After Strong Kosdaq Debut | MT |
Business description: GC Genome Corporation

Executive Committee: GC Genome Corporation
| Manager | Title | Age | Since |
|---|---|---|---|
Chang-Seok Gi
CEO | Chief Executive Officer | 57 | 2020-03-25 |
Sang-Hun Jeong
DFI | Director of Finance/CFO | 50 | 2025-03-26 |
Seu-Nga Hyun
AUD | Comptroller/Controller/Auditor | 45 | 2024-03-28 |
Eun-Hae Jo
PRN | Corporate Officer/Principal | 52 | - |
Composition of the Board of Directors: GC Genome Corporation
| Director | Title | Age | Since |
|---|---|---|---|
Sang-Uk Kim
BRD | Director/Board Member | 57 | 2023-03-29 |
Company details: GC Genome Corporation

Medical & Diagnostic Laboratories
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
| -7.39% | -5.27% | -26.27% | - | 98.8M | ||
| +1.62% | +6.57% | +103.95% | +501.40% | 46.82B | ||
| +0.99% | +5.45% | +21.31% | +55.58% | 26.99B | ||
| -1.40% | -5.89% | -26.65% | -35.28% | 7.52B | ||
| +0.19% | +1.58% | +13.04% | +153.96% | 6.06B | ||
| +0.25% | -3.77% | +9.78% | +68.98% | 3.3B | ||
| +3.71% | +9.77% | -29.00% | +1,747.20% | 2.46B | ||
| +3.06% | +6.46% | +174.60% | +20.53% | 2.12B | ||
| +1.92% | +2.65% | +2.35% | -50.31% | 2.12B | ||
| +1.92% | +2.14% | +33.96% | +21.62% | 1.9B | ||
| Average | +0.46% | +0.52% | +27.71% | +275.96% | 9.94B | |
| Weighted average by Cap. | +1.09% | +2.67% | +57.54% | +303.64% |
Sector
Annual profits - Rate of surprise
- Stock Market
- Stocks
- A340450 Stock
- Company GC Genome Corporation
Select your edition
All financial news and data tailored to specific country editions

















